Orthofix medical CEO Calafiore Massimo buys $172,801 in stock

Published 06/03/2025, 22:48
Orthofix medical CEO Calafiore Massimo buys $172,801 in stock

Calafiore Massimo, President and CEO of Orthofix Medical (TASE:BLWV) Inc. (NASDAQ:OFIX), recently acquired 9,914 shares of the company’s common stock. The purchase, completed on March 5, 2025, was executed at a weighted average price of $17.43 per share, with a price range between $17.265 and $17.595. The total transaction amounted to approximately $172,801. The medical device company, with a market capitalization of $658 million, maintains strong liquidity with a current ratio of 2.57. Following this acquisition, Massimo now holds 222,404 shares of Orthofix Medical, including previously reported restricted stock units. According to InvestingPro analysis, the stock appears undervalued, with analyst price targets ranging from $22 to $27.20 per share. Get access to more detailed insights and 6 additional ProTips for OFIX through InvestingPro’s comprehensive research reports.

In other recent news, Orthofix International reported fourth-quarter earnings with revenue reaching $215.7 million, a 7.6% increase from the previous year, surpassing the consensus estimate of $212.7 million. The company’s adjusted EBITDA also exceeded expectations at $23.9 million, driven by strong performance in its Global Orthopedics segment and BioStim. However, Orthofix’s revenue guidance for fiscal year 2025, set between $818 million and $826 million, fell short of analysts’ projections due to the discontinuation of certain product lines. Despite this, Orthofix expects adjusted EBITDA for FY25 to range between $82 million and $86 million, with a focus on profitable growth. BTIG maintained a Neutral rating on Orthofix, noting potential challenges in the first quarter of FY25 and a moderate growth trajectory. Meanwhile, Canaccord Genuity initiated coverage with a Buy rating and a $24 price target, expressing optimism about Orthofix’s integration efforts following its merger with SeaSpine. The firm highlighted Orthofix’s strategic focus on innovation and margin expansion, viewing the current stock valuation as attractive.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.